Source: Annual Congress 2010 - Airway smooth muscle cells



Rating:

Share or cite this content

Citations should be made in the following way:
D. Jungck, J. Knobloch, K. Urban, B. Grensemann, E. Stoelben, J. Strauch, A. Koch (Cologne, Germany). The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan. Eur Respir J 2010; 36: Suppl. 54, 2368

Member's Comments

No comment yet.

Related content which might interest you: Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407 Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007 The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 415s Year: 2003 Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006 Effect of long-acting β2 adrenergic receptor agonists and glucocorticoids on extracellular matrix production Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005 Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004 Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012